Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming - Takeaways - MDSpire

Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming

  • By

  • Egiroh Omene

  • July 14, 2026

Share

  • 1

    Glioblastoma (GBM) is the most lethal primary brain tumor, with a median overall survival of 14 to 16 months despite current treatment strategies.

  • 2

    The immunosuppressive tumor microenvironment (TME) in GBM is characterized by metabolic competition among tumor cells, myeloid cells, and T lymphocytes.

  • 3

    Aerobic glycolysis in GBM cells produces lactate, polarizing macrophages toward immunosuppressive phenotypes and impairing T cell function.

  • 4

    Disrupting glucose and glutamine metabolism can reprogram the immunosuppressive myeloid compartment while preserving T cell fitness.

  • 5

    Pharmacological interventions targeting metabolic competition may enhance anti-tumor immunity and are supported by preclinical and early-phase clinical data.

Original Source(s)

Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming

  • by Egiroh Omene

  • July 14, 2026

Related Content

Trends in liver failure-related mortality among middle-aged and older adults with digestive system malignant tumors in the United States, 1999–2023

A prehabilitation-enhanced nomogram for predicting early pulmonary recovery failure after lung tumor surgery: development and multicenter validation

A metabolic marker–based diagnostic model for precancerous and malignant endometrial lesions in insulin-resistant PCOS women with sonographically suspected endometrial polyps